Transplantation: BENEFIT of belatacept: kidney transplantation moves forward

Nature Reviews Nephrology 12, 261 (2016). doi:10.1038/nrneph.2016.34 Authors: Maarten Naesens & Olivier Thaunat New data from the BENEFIT study demonstrate that belatacept improves long-term allograft and patient survival after kidney transplantation, despite higher rates of biopsy-proven acute rejection than with ciclosporin. The noninferiority design of BENEFIT represents a feasible strategy to further the development of innovator drugs to reduce late graft loss.
Source: Nature Reviews Nephrology - Category: Urology & Nephrology Authors: Tags: News and Views Source Type: research